Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Serplulimab Combined With Standard Chemotherapy in Neuroendocrine Carcinoma
NCT05747729Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, serplulimab in neuroendocrine carcinoma (NEC). Started Jun 2023; status: recruiting.
02
Drugs
surufatinibserplulimab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05747729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747729.